Work

Abstract CT252: A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies

Year: 2023

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2023-ct252

Authors: Andrew G. Gianoukakis, Susanne Arnold, Saad Khan, Matthew Taylor, Hendrik-Tobias Arkenau, Liz Clark, Geoffrey Fisher, Vivek Subbiah

Institutions: University of California, Los Angeles, The Lundquist Institute, Harbor–UCLA Medical Center, University of Kentucky, Stanford University, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4365512115

Cites:

Cited by:

Related to: 10